DelveInsight’s “HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the HER2+ Gastric Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging HER2+ Gastric Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current HER2+ Gastric Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
HER2+ Gastric Cancer: An Overview
Gastric cancer (GC) is a disease in which malignant (cancer) cells form in the stomach lining. It is a biologically heterogeneous tumor. The identification of human epidermal growth factor receptor-2 (HER2) biomarker overexpression in GC represented a significant step toward unraveling the molecular complexity of this disease.
Overexpression of HER2 protein in gastric cancer, using immunohistochemistry (IHC), was first described in 1986. In the 1990s, some series reported 9–38% of HER2-positive (+) tumors using polyclonal antibodies directed against different domains of HER2 protein and restricting the evaluation to the staining of the cell membrane.
The development of GC is a multifactorial process, and many conditions influence the likelihood of occurrence. Of them, family history of gastric cancer, Helicobacter pylori infection (a common bacterium that can also cause stomach ulcers), history of an adenomatous gastric polyp larger than 2 cm, history of chronic atrophic gastritis, history of pernicious anemia, obesity, alcohol, smoking, red meat, and low socioeconomic status are all believed to be important.
The reasons for the selective overexpression of HER2 in intestinal-type gastric carcinomas are complex, and it is necessary to investigate them in depth. The association of this oncogene with a specific histologic tumor type indicates that certain characteristics (e.g., HER2 overexpression and intestinal phenotype) may be expressed preferentially. Although HER2-positivity selects the patients most likely to benefit from HER2-targeted therapy, some patients with HER2-positive GC experience primary resistance to HER2-directed therapy.
HER2+ Gastric Cancer Market Key Facts
-
The total incident population of HER2-Positive Gastric Cancer in 7MM was estimated at approximately 51,000 cases in 2022 and is expected to increase during the forecast period (2023–2032). Among all the 7MM countries, the highest incidence of HER2-Positive gastric cancer was recorded in Japan and the lowest incidence was found in the United Kingdom.
-
The United States recorded a total of approximately 5,800 incident cases of HER2-Positive gastric cancer in 2022. There were a total of nearly 12,000 incident cases in the EU4 and the UK region. Among these five countries, the highest number of incident cases was recorded in Germany. All these cases are anticipated to be increasing during the forecast period (2023–2032).
-
During the year 2022, there were approximately 3,600 males and 2,200 females affected with HER2-Positive Gastric Cancer in the United States.
-
According to DelveInsight, HER2-Positive Gastric Cancer is more common in males than females.
-
The highest number of cases of HER2-Positive Gastric Cancer were observed in the 75+ years of age group. In Japan, there were approximately 17,000 incident cases in this age group in 2022. This count is anticipated to increase by the end of the forecast period.
-
The FDA granted Orphan Drug Designation to the off-the-shelf natural killer (NK) cell therapy CYNK-101 in February 2022, as a potential treatment for patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging HER2+ Gastric Cancer pipeline therapies. It also thoroughly assesses the HER2+ Gastric Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed HER2+ Gastric Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
HER2+ Gastric Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted HER2+ Gastric Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted HER2+ Gastric Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the HER2+ Gastric Cancer Epidemiology, Segmented as –
-
Incident Cases of HER2+ Gastric Cancer in the 7MM [2019–2032]
-
Gender-specific cases of HER2+ Gastric Cancer in the 7MM [2019–2032]
-
Age-specific Cases of HER2+ Gastric Cancer in the 7MM [2019–2032]
-
Stage-specific cases of HER2+ Gastric Cancer in the 7MM [2019–2032]
-
Line-wise Treated Cases of HER2+ Gastric Cancer (Neoadjuvant/Adjuvant, 1L,and 2L+) in the 7MM [2019–2032]
HER2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the HER2+ Gastric Cancer market or expected to be launched during the study period. The analysis covers the HER2+ Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the HER2+ Gastric Cancer drugs based on their sale and market share.
The report also covers the HER2+ Gastric Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key HER2+ Gastric Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the HER2+ Gastric Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
HER2+ Gastric Cancer Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for HER2 Positive Gastric Cancer. Currently, Pieris Pharmaceuticals is leading the therapeutics market with its HER2 HER2-positive gastric Cancer drug candidates in the most advanced stage of clinical development
HER2+ Gastric Cancer Companies Actively Working in the Therapeutics Market Include
AstraZeneca, Bayer, Bristol-Myers Squibb, Loxo Oncology, Ono Pharmaceutical, Daiichi Sankyo Inc., Elevar Therapeutic, Eli Lilly, Genentech, Hutchison Medipharma Limited, Innovent Biologics, Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, LintonPharm, MacroGenics, Zai Lab, Merck, Eisai Inc., Merus N.V., OncXerna Therapeutics, Inc., Qilu Pharmaceutical Co., Ltd., Remegen Biosciences, Roche, Seagen, Shanghai Henlius Biotech, and many others
Emerging and Marketed HER2+ Gastric Cancer Therapies Covered in the Report Include:
-
Cinrebafusp alfa: Pieris Pharmaceuticals
-
BI-1607: BioInvent International
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. HER2+ Gastric Cancer Competitive Intelligence Analysis
4. HER2+ Gastric Cancer Market Overview at a Glance
5. HER2+ Gastric Cancer Disease Background and Overview
6. HER2+ Gastric Cancer Patient Journey
7. HER2+ Gastric Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. HER2+ Gastric Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. HER2+ Gastric Cancer Unmet Needs
10. Key Endpoints of HER2+ Gastric Cancer Treatment
11. HER2+ Gastric Cancer Marketed Therapies
12. HER2+ Gastric Cancer Emerging Drugs and Latest Therapeutic Advances
13. HER2+ Gastric Cancer Seven Major Market Analysis
14. Attribute Analysis
15. HER2+ Gastric Cancer Market Outlook (In US, EU5, and Japan)
16. HER2+ Gastric Cancer Companies Active in the Market
17. HER2+ Gastric Cancer Access and Reimbursement Overview
18. KOL Views on the HER2+ Gastric Cancer Market
19. HER2+ Gastric Cancer Market Drivers
20. HER2+ Gastric Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
“Hepatitis C Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hepatitis C market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hepatitis C market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices